OBJECTIVES: This study aimed to build a prediction score of prognosis for patients with advanced hepatocellular carcinoma (HCC) after sorafenib treatment. METHODS: A total of 165 patients with advanced HCC who were treated with sorafenib were analyzed. Readily available baseline factors were used to establish a scoring system for the prediction of survival. RESULTS: The median survival time (MST) was 14.2 months. The independent prognostic factors were C-reactive protein (CRP) <1.0 mg/dL [hazard ratio (HR) =0.51], albumin >3.5 g/dL (HR =0.55), alpha-fetoprotein <200 ng/mL (HR =0.45), and a lack of major vascular invasion (HR =0.39). Each of these factors had a score of 1, and after classifying the patients into five groups, the total scores ranged from 0 to 4. Higher scores were linked to significantly longer survival (p<0.0001). Twenty-nine patients (17.6%) with a score of 4 had a MST as long as 36.5 months, whereas MST was as short as 2.4 and 3.7 months for seven (4.2%) and 22 (13.3%) patients with scores of 0 and 1, respectively. CONCLUSIONS: A novel prognostic scoring system, which includes the CRP level, has the ability to stratify the prognosis of patients with advanced stage HCC after treatment with sorafenib.
OBJECTIVES: This study aimed to build a prediction score of prognosis for patients with advanced hepatocellular carcinoma (HCC) after sorafenib treatment. METHODS: A total of 165 patients with advanced HCC who were treated with sorafenib were analyzed. Readily available baseline factors were used to establish a scoring system for the prediction of survival. RESULTS: The median survival time (MST) was 14.2 months. The independent prognostic factors were C-reactive protein (CRP) <1.0 mg/dL [hazard ratio (HR) =0.51], albumin >3.5 g/dL (HR =0.55), alpha-fetoprotein <200 ng/mL (HR =0.45), and a lack of major vascular invasion (HR =0.39). Each of these factors had a score of 1, and after classifying the patients into five groups, the total scores ranged from 0 to 4. Higher scores were linked to significantly longer survival (p<0.0001). Twenty-nine patients (17.6%) with a score of 4 had a MST as long as 36.5 months, whereas MST was as short as 2.4 and 3.7 months for seven (4.2%) and 22 (13.3%) patients with scores of 0 and 1, respectively. CONCLUSIONS: A novel prognostic scoring system, which includes the CRP level, has the ability to stratify the prognosis of patients with advanced stage HCC after treatment with sorafenib.
Authors: Augusto Villanueva; Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Clara Alsinet; Radoslav Savic; Helena Cornella; Josep M Llovet Journal: Clin Cancer Res Date: 2010-08-16 Impact factor: 12.531
Authors: Arno Kornberg; Martina Schernhammer; Jennifer Kornberg; Helmut Friess; Katharina Thrum Journal: Dig Dis Sci Date: 2018-09-27 Impact factor: 3.199
Authors: Martin F Sprinzl; Martha M Kirstein; Sandra Koch; Marie-Luise Seib; Julia Weinmann-Menke; Hauke Lang; Christoph Düber; Gerrit Toenges; Daniela Zöller; Jens U Marquardt; Marcus-Alexander Wörns; Peter R Galle; Arndt Vogel; Matthias Pinter; Arndt Weinmann Journal: Liver Cancer Date: 2018-10-04 Impact factor: 11.740
Authors: James S Leathers; Domingo Balderramo; Jhon Prieto; Fernando Diehl; Esteban Gonzalez-Ballerga; Melina R Ferreiro; Enrique Carrera; Fernando Barreyro; Javier Diaz-Ferrer; Dupinder Singh; Angelo Z Mattos; Flair Carrilho; Jose D Debes Journal: Hepat Mon Date: 2018-10-21 Impact factor: 0.660
Authors: Tobias Meischl; Susanne Rasoul-Rockenschaub; Georg Györi; Wolfgang Sieghart; Thomas Reiberger; Michael Trauner; Thomas Soliman; Gabriela Berlakovich; Matthias Pinter Journal: PLoS One Date: 2019-05-29 Impact factor: 3.240